Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Restless Leg Syndrome (RLS) Clear all
Completed Not applicable Interventional

Cranial Electrotherapy for Military Beneficiaries With Restless Legs Syndrome

NCT02419014
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Active CES Device Alpha-Stim®, Sham Device
Device
Lead sponsor
Tripler Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 3 Interventional Results available

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

NCT00806026
View directory record Official record
Conditions
Idiopathic Restless Legs Syndrome
Interventions
placebo and pregabalin, pramipexol, Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Jasper, Alabama • Tuscaloosa, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional Results available

A Study on the Use of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome

NCT02526277
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
MMF07 Foot Massager, Heat Therapy
Device
Lead sponsor
Ariane Park
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 4 Interventional

12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome

NCT00373542
View directory record Official record
Conditions
Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions
ropinirole CR-RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Jasper, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Jul 21, 2026, 7:11 AM EDT
Completed No phase listed Observational

Comparison of Dialysis Therapies on Cognitive Function

NCT00597103
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 2 Interventional Results available

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

NCT01495793
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Jul 21, 2026, 7:11 AM EDT
Terminated Phase 4 Interventional

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

NCT02117076
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
Gabapentin immediate release, Gabapentin enacarbil extended release
Drug
Lead sponsor
Theresa Zesiewicz, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 21, 2026, 7:11 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

NCT06570941
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Chylobinoid Topical Cream
Drug
Lead sponsor
Synthonics Inc
Industry
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 3 Interventional

Sequential Compression Devices for Treatment of Restless Legs Syndrome

NCT00479531
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
AirCast Sequential Compression Device
Device
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Sleep Disorders Center, Walter Reed Army Medical Center, District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Jul 21, 2026, 7:11 AM EDT
Withdrawn Not applicable Interventional

Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study

NCT01861652
View directory record Official record
Conditions
Restless Legs Syndrome,, Restless Legs,, Ekbom Syndrome
Interventions
Venous Health Systems Vasculaire Leg Compression Device
Device
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

NCT01521663
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
IPX159, Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Brimingham, Alabama • Little Rock, Arkansas • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 21, 2026, 7:11 AM EDT
Completed No phase listed Observational

New Data Analysis Methods for Actigraphy in Sleep Medicine

NCT00949858
View directory record Official record
Conditions
Obstructive Sleep Apnea, Restless Leg Syndrome, Insomnia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Disorders Management, Health and Safety in Police

NCT00207285
View directory record Official record
Conditions
Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions
Sleep Hygiene Education, Screening and Treatment of Sleep Disorders
Behavioral · Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional

Efficacy of BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study

NCT04061681
View directory record Official record
Conditions
Multiple Sclerosis, Restless Legs Syndrome
Interventions
Behavioral Intervention (BIPAMS)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 21, 2026, 7:11 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

NCT03728933
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine 1 milligram/24 hours, Rotigotine 2 milligram/24 hours, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
13 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jul 21, 2026, 7:11 AM EDT
Recruiting Phase 4 Interventional

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

NCT03082755
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gabapentin Enacarbil, Placebo Oral Tablet
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
55 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Not applicable Interventional

RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome

NCT02386423
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
RESTIFFIC™ Brand Pressure Application System
Device
Lead sponsor
Lake Erie Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 2 Interventional

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00247364
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
Sleep Health Centers
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2005 · Synced Jul 21, 2026, 7:11 AM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Bupropion and Restless Legs Syndrome

NCT00621517
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Bupropion, Placebo
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jul 21, 2026, 7:11 AM EDT
Terminated Phase 2 Interventional Results available

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

NCT02826681
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 21, 2026, 7:11 AM EDT
Completed Phase 3 Interventional

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

NCT00363857
View directory record Official record
Conditions
Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions
Ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
49
States / cities
Alabaster, Alabama • Birmingham, Alabama • Jasper, Alabama + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Jul 21, 2026, 7:11 AM EDT